Capstone Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.7M | Sell |
58,200
-4,600
| -7% | -$1.02M | 0.02% | 254 |
|
|
2025
Q4 | $14.3M | Sell |
62,800
-15,000
| -19% | -$3.42M | 0.03% | 217 |
|
|
2025
Q3 | $18M | Buy |
77,800
+17,400
| +29% | +$3.54M | 0.03% | 220 |
|
|
2025
Q2 | $11.2M | Sell |
60,400
-42,200
| -41% | -$7.84M | 0.03% | 225 |
|
|
2025
Q1 | $21.5M | Sell |
102,600
-82,300
| -45% | -$16M | 0.06% | 161 |
|
|
2024
Q4 | $32.9M | Buy |
184,900
+46,400
| +34% | +$8.53M | 0.08% | 147 |
|
|
2024
Q3 | $27.4M | Buy |
138,500
+26,400
| +24% | +$4.93M | 0.08% | 141 |
|
|
2024
Q2 | $19.2M | Buy |
112,100
+9,400
| +9% | +$1.56M | 0.06% | 197 |
|
|
2024
Q1 | $18.7M | Sell |
102,700
-260,400
| -72% | -$44.9M | 0.07% | 188 |
|
|
2023
Q4 | $56.3M | Buy |
363,100
+121,100
| +50% | +$17.7M | 0.17% | 87 |
|
|
2023
Q3 | $36.1M | Buy |
242,000
+22,300
| +10% | +$3.27M | 0.16% | 85 |
|
|
2023
Q2 | $29.6M | Buy |
219,700
+10,700
| +5% | +$1.57M | 0.15% | 91 |
|
|
2023
Q1 | $33.3M | Buy |
209,000
+119,000
| +132% | +$18.2M | 0.17% | 67 |
|
|
2022
Q4 | $14.5M | Buy |
90,000
+600
| +0.7% | +$92K | 0.11% | 163 |
|
|
2022
Q3 | $12M | Buy |
89,400
+4,600
| +5% | +$660K | 0.07% | 195 |
|
|
2022
Q2 | $13M | Sell |
84,800
-125,800
| -60% | -$19.2M | 0.06% | 200 |
|
|
2022
Q1 | $34.1M | Sell |
210,600
-164,100
| -44% | -$23.8M | 0.09% | 166 |
|
|
2021
Q4 | $50.7M | Buy |
374,700
+14,800
| +4% | +$1.75M | 0.08% | 196 |
|
|
2021
Q3 | $38.8M | Sell |
359,900
-21,500
| -6% | -$2.46M | 0.08% | 239 |
|
|
2021
Q2 | $43M | Buy |
381,400
+87,600
| +30% | +$9.87M | 0.1% | 184 |
|
|
2021
Q1 | $31.8M | Sell |
293,800
-8,200
| -3% | -$877K | 0.09% | 200 |
|
|
2020
Q4 | $32.4M | Buy |
302,000
+121,900
| +68% | +$11.7M | 0.11% | 154 |
|
|
2020
Q3 | $15.8M | Buy |
180,100
+35,200
| +24% | +$3.31M | 0.08% | 216 |
|
|
2020
Q2 | $14.2M | Buy |
144,900
+102,800
| +244% | +$9.05M | 0.09% | 181 |
|
|
2020
Q1 | $3.21M | Sell |
42,100
-124,800
| -75% | -$10.6M | 0.05% | 389 |
|
|
2019
Q4 | $14.8M | Buy |
166,900
+35,500
| +27% | +$2.95M | 0.08% | 256 |
|
|
2019
Q3 | $9.95M | Sell |
131,400
-144,800
| -52% | -$9.93M | 0.07% | 290 |
|
|
2019
Q2 | $20.1M | Buy |
276,200
+171,900
| +165% | +$13.5M | 0.15% | 155 |
|
|
2019
Q1 | $8.41M | Buy |
104,300
+63,400
| +155% | +$5.19M | 0.08% | 246 |
|
|
2018
Q4 | $3.77M | Buy |
40,900
+7,600
| +23% | +$668K | 0.05% | 310 |
|
|
2018
Q3 | $3.15M | Buy |
33,300
+24,400
| +274% | +$2.31M | 0.04% | 337 |
|
|
2018
Q2 | $825K | Buy |
+8,900
| New | +$869K | 0.01% | 411 |
|
|
2017
Q4 | – | Sell |
-9,500
| Closed | -$843K | – | 479 |
|
|
2017
Q3 | $843K | Hold |
9,500
| – | – | 0.03% | 247 |
|
|
2017
Q2 | $688K | Sell |
9,500
-5,400
| -36% | -$363K | 0.02% | 373 |
|
|
2017
Q1 | $969K | Hold |
14,900
| – | – | 0.02% | 438 |
|
|
2016
Q4 | $932K | Buy |
+14,900
| New | +$909K | 0.03% | 444 |
|
Other funds holding ABBV
VCM
VPM
Capstone Investment Advisors's ABBV Position: Q1 2026 in Review
Capstone Investment Advisors reduced its AbbVie (ABBV) stake by 9% in Q1 2026, selling an estimated $105K and leaving 4,761 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #854.
Capstone Investment Advisors first reported a position in ABBV in Q4 2015 and has held it in 28 quarters since. The position peaked at $8.41M in Q3 2021. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Capstone Investment Advisors held 4,761 shares of AbbVie worth $1.04M as of Q1 2026.
- Capstone Investment Advisors sold 472 AbbVie shares in Q1 2026, an estimated $105K.
- AbbVie made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #854 holding.
- Capstone Investment Advisors first reported a position in AbbVie in Q4 2015 and has held it in 28 quarters since.
- Capstone Investment Advisors's AbbVie position peaked at $8.41M in Q3 2021.
- 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.